N4 Pharma Plc (AIM:N4P)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.3750
+0.0225 (6.00%)
Jul 18, 2025, 4:35 PM GMT+1
-16.67%
Market Cap3.12M
Revenue (ttm)7.28K
Net Income (ttm)-1.06M
Shares Out832.28M
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume979,840
Average Volume881,482
Open0.3500
Previous Close0.3750
Day's Range0.3500 - 0.4000
52-Week Range0.3500 - 0.8000
Beta0.69
RSI30.93
Earnings DateJun 24, 2025

About N4 Pharma

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-cl... [Read more]

Sector Healthcare
Founded 1979
Employees 4
Stock Exchange London Stock Exchange AIM
Ticker Symbol N4P
Full Company Profile

Financial Performance

In 2024, N4 Pharma's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements

News

There is no news available yet.